Rapamycin and Alzheimer Disease: a Hypothesis for the Effective use of Rapamycin

[adssx]

Thanks @Raquel. The ERAP paper is discussed there so I’m closing this thread to avoid duplicating the discussion:

Evaluation of rapamycin as a neuroprotective treatment in Alzheimer’s disease (ERAP): a 6-month trial

Pre-print publication so preliminary. 7 mg weekly dose for 26 weeks. Several CSF biomarkers increased (including total tau) indicative of possible neuron injury. Some Increases in brain glucose metabolism seen which is positive. Overall, kind of a mixed bag IMHO.